Impulse News

FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the JACC: Heart Failure

Orangeburg, New York, May 10, 2018 – Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure. The study results were presented by Prof. William Abraham, MD, Professor of Internal Medicine and Director, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, at the […]

Mehr dazu

The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China

Orangeburg, New York & Stuttgart, Germany. December 18, 2017 – The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure.  The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou.  “This is a major milestone for Impulse Dynamics, as it will help […]

Mehr dazu

– „I feel like I have won the lottery!“

Ulla Magnusson, today 80 years old, was implanted with an Optimizer® device for cardiac contractility modulation treatment of her chronic heart failure at Karolinska university hospital two years ago. Ulla describes how fatigue and shortness of breath started to take over her life about 5 years ago and how it affected her everyday living: “It […]

Mehr dazu

New device based treatment for patients with Chronic Heart Failure now available in the Nordic region

Cardiac contractility modulation (CCM™) is a device based therapy which EU Studies have shown to be an effective treatment option for patients with Chronic Heart Failure (CHF). CCM™ therapy will now be made available to patients in the Nordic region by consultation with their treating doctors. An estimated 250 000 individuals in Sweden suffer from […]

Mehr dazu

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study.

Orangeburg, New York. August 7, 2017 – Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm Continued Access evaluation of the company’s Cardiac Contractility Modulation (CCM™) device. Impulse Dynamics proprietary CCM™ technology delivers non-excitatory electric pulses to the cardiac muscle with the […]

Mehr dazu
Seite 1 von 912345...Letzte »